Good afternoon, everyone. Thank you for standing by. Welcome to CytomX Therapeutics third quarter, 2024 Financial results call. Please be advised that today's call is being recorded. I would now like ...

Two first-line cutaneous melanoma patients - one patient who was dose escalated from 70 mg to 210 mg and finally to 350 mg experienced a confirmed partial response (PR) at the higher dose; one patient ...

The Hamilton scientists were able to map a CWD prion, the misfolded protein that causes the deadly brain disease, to the near-atomic level.

Good morning, and welcome to Y-mAbs Therapeutics Inc. Third Quarter Conference Call for 2024. At this time, all participants are in a listen-only mode. Instruction for the question-and-answer session ...

This important manuscript provides insights into the competition between Splicing Factor 1 (SF1) and Quaking (QKI) for binding at the ACUAA branch point sequence in a model intron, regulating exon ...

Members of Medigene management as expert speakers, Prof. Dolores Schendel, Chief Scientific Officer and Kirsty Crame, MD, Vice President, Clinical Strategy & Development Presentations and seminars ...

Blocking a protein that imports lactic acid, a metabolic byproduct of cancer cells, reinvigorated exhausted T cells and led to improved tumor control in mouse models of cancer, according to a new ...

Bharti says it isn’t clear what exactly caused the vision improvements. It’s possible that the transplanted cells themselves ...

This work is an important contribution to understanding the role of FGF signaling in the induction of primitive-like cells in a 2D system of human gastrulation. The authors provide compelling evidence ...

CAR-T cell therapy, a marvel of bioengineering, takes a patient’s own immune cells and reprograms them to attack cells ...